Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PDE2A | O00408 | 5/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 4/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31256398 | 1.00 | ALDH1A1 (0.48) | ALDH1A1TDP1KDM4EPDE2ATSHR | |
| SCHEMBL9404028 | 0.83 | KDM4E (0.48) | ALDH1A1TDP1KDM4EPDE2ATSHR | |
| SCHEMBL10525468 | 0.78 | PDE2A (0.46) | ALDH1A1TDP1KDM4EPDE2A | |
| SCHEMBL18856709 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TDP1KDM4EPDE2ATSHR | |
| SCHEMBL1403756 | 0.78 | PDE7A (0.53) | ALDH1A1TDP1KDM4EPDE2ATSHR | |
| SCHEMBL30875154 | 0.78 | PDE7A (0.53) | ALDH1A1TDP1KDM4EPDE2ATSHR | |
| SCHEMBL9404029 | 0.78 | KDM4E (0.47) | ALDH1A1TDP1KDM4EPDE2ATSHR | |
| SCHEMBL9404050 | 0.76 | PDE2A (0.45) | ALDH1A1TDP1KDM4EPDE2ATSHR | |
| SCHEMBL18247943 | 0.75 | PDE2A (0.44) | ALDH1A1TDP1KDM4EPDE2APOLB | |
| SCHEMBL900648 | 0.75 | PDE2A (0.44) | ALDH1A1TDP1KDM4EPDE2AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10991972-B2 | Electrolyte solution, positive electrode, and lithium-ion battery comprising the electrolyte solution and/or the positive electrode | BYD COMPANY LIMITED (CN) | 2021-04-27 | — | — | US | claimed |
| US-20190036156-A1 | ELECTROLYTE SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY COMPRISING THE ELECTROLYTE SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD COMPANY LIMITED (CN) | 2019-01-31 | — | — | US | claimed |
| EP-3407416-A1 | ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY CONTAINING THE ELECTROLYTIC SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD Company Limited (CN) | 2018-11-28 | — | — | EP | claimed |
| EP-0315862-B1 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1994-04-13 | — | — | EP | claimed |
| EP-0315862-A2 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1989-05-17 | — | — | EP | claimed |
| US-10991972-B2 | Electrolyte solution, positive electrode, and lithium-ion battery comprising the electrolyte solution and/or the positive electrode | BYD COMPANY LIMITED (CN) | 2021-04-27 | — | — | US | disclosed |
| US-10991972-B2 | Electrolyte solution, positive electrode, and lithium-ion battery comprising the electrolyte solution and/or the positive electrode | BYD COMPANY LIMITED (CN) | 2021-04-27 | — | — | US | disclosed |
| EP-3087060-B1 | PYRIMIDONE CARBOXAMIDE COMPOUNDS AS PDE2 INHIBITORS | MERCK SHARP & DOHME (US) | 2020-05-13 | — | — | EP | disclosed |
| US-10285989-B2 | Pyrimidinone amide compounds as PDE2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190036156-A1 | ELECTROLYTE SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY COMPRISING THE ELECTROLYTE SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD COMPANY LIMITED (CN) | 2019-01-31 | — | — | US | disclosed |
| US-20190036156-A1 | ELECTROLYTE SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY COMPRISING THE ELECTROLYTE SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD COMPANY LIMITED (CN) | 2019-01-31 | — | — | US | disclosed |
| EP-3407416-A1 | ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE, AND LITHIUM-ION BATTERY CONTAINING THE ELECTROLYTIC SOLUTION AND/OR THE POSITIVE ELECTRODE | BYD Company Limited (CN) | 2018-11-28 | — | — | EP | disclosed |
| EP-2858988-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | Novartis AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-20140343086-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-8829195-B2 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | NOVARTIS AG (CH) | 2014-09-09 | — | — | US | disclosed |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | US | disclosed |
| WO-2013171640-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| WO-2013171639-A1 | BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | NOVARTIS AG (CH) | 2013-11-21 | — | — | WO | disclosed |
| EP-0315862-B1 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1994-04-13 | — | — | EP | disclosed |
| EP-0315862-A2 | Aromatically fluorinated fluoromethoxy- and fluoromethylthio-amino benzenes and their preparation | BAYER AG (DE) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343086-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ALDH1A1 1602/4885TDP1 1679/4885KDM4E 587/4885 |
| US-10285989-B2 | Pyrimidinone amide compounds as PDE2 inhibitors | PDE12, PDE2A, PDE4D | ALDH1A1 1640/4885TDP1 102/4885KDM4E 2289/4885 |
| US-20130310395-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1 | ABL1, ABL2, BCR | ALDH1A1 1602/4885TDP1 1679/4885KDM4E 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.